139 related articles for article (PubMed ID: 16091734)
21. Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor.
Qian S; Somlo G; Zhou B; Zhu L; Mi S; Mo X; Cheung EM; Qiu W; Lin RJ; Rossi J; Holtz M; Chu P; Yen Y
Oligonucleotides; 2005; 15(1):1-11. PubMed ID: 15788896
[TBL] [Abstract][Full Text] [Related]
22. Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.
Maeda T; Yagasaki F; Ishikawa M; Takahashi N; Bessho M
Blood; 2005 Mar; 105(5):2115-23. PubMed ID: 15514005
[TBL] [Abstract][Full Text] [Related]
23. A central nervous system specific mouse model for thanatophoric dysplasia type II.
Lin T; Sandusky SB; Xue H; Fishbein KW; Spencer RG; Rao MS; Francomano CA
Hum Mol Genet; 2003 Nov; 12(21):2863-71. PubMed ID: 12966031
[TBL] [Abstract][Full Text] [Related]
24. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.
Webster MK; D'Avis PY; Robertson SC; Donoghue DJ
Mol Cell Biol; 1996 Aug; 16(8):4081-7. PubMed ID: 8754806
[TBL] [Abstract][Full Text] [Related]
25. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Chesi M; Brents LA; Ely SA; Bais C; Robbiani DF; Mesri EA; Kuehl WM; Bergsagel PL
Blood; 2001 Feb; 97(3):729-36. PubMed ID: 11157491
[TBL] [Abstract][Full Text] [Related]
26. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B
Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917
[TBL] [Abstract][Full Text] [Related]
27. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells.
Trudel S; Stewart AK; Rom E; Wei E; Li ZH; Kotzer S; Chumakov I; Singer Y; Chang H; Liang SB; Yayon A
Blood; 2006 May; 107(10):4039-46. PubMed ID: 16467200
[TBL] [Abstract][Full Text] [Related]
28. Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II.
Shung CY; Ota S; Zhou ZQ; Keene DR; Hurlin PJ
Hum Mol Genet; 2012 Nov; 21(21):4628-44. PubMed ID: 22843502
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast growth factor receptor 3 (FGFR3) expression in malignant lymphomas.
Larson A; Cook JR
Appl Immunohistochem Mol Morphol; 2008 Jul; 16(4):322-5. PubMed ID: 18528286
[TBL] [Abstract][Full Text] [Related]
30. N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells.
Bahlis NJ; Miao Y; Koc ON; Lee K; Boise LH; Gerson SL
Leuk Lymphoma; 2005 Jun; 46(6):899-908. PubMed ID: 16019536
[TBL] [Abstract][Full Text] [Related]
31. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.
Kang S; Dong S; Gu TL; Guo A; Cohen MS; Lonial S; Khoury HJ; Fabbro D; Gilliland DG; Bergsagel PL; Taunton J; Polakiewicz RD; Chen J
Cancer Cell; 2007 Sep; 12(3):201-14. PubMed ID: 17785202
[TBL] [Abstract][Full Text] [Related]
32. Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
de Brito LR; Batey MA; Zhao Y; Squires MS; Maitland H; Leung HY; Hall AG; Jackson G; Newell DR; Irving JA
Leuk Res; 2011 Sep; 35(9):1233-40. PubMed ID: 21316102
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.
Trudel S; Ely S; Farooqi Y; Affer M; Robbiani DF; Chesi M; Bergsagel PL
Blood; 2004 May; 103(9):3521-8. PubMed ID: 14715624
[TBL] [Abstract][Full Text] [Related]
34. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.
Krejci P; Murakami S; Prochazkova J; Trantirek L; Chlebova K; Ouyang Z; Aklian A; Smutny J; Bryja V; Kozubik A; Wilcox WR
J Biol Chem; 2010 Jul; 285(27):20644-53. PubMed ID: 20439987
[TBL] [Abstract][Full Text] [Related]
35. PKC412--a protein kinase inhibitor with a broad therapeutic potential.
Fabbro D; Ruetz S; Bodis S; Pruschy M; Csermak K; Man A; Campochiaro P; Wood J; O'Reilly T; Meyer T
Anticancer Drug Des; 2000 Feb; 15(1):17-28. PubMed ID: 10888033
[TBL] [Abstract][Full Text] [Related]
36. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation.
Yagasaki F; Wakao D; Yokoyama Y; Uchida Y; Murohashi I; Kayano H; Taniwaki M; Matsuda A; Bessho M
Cancer Res; 2001 Dec; 61(23):8371-4. PubMed ID: 11731410
[TBL] [Abstract][Full Text] [Related]
37. ETV6-NTRK3 as a therapeutic target of small molecule inhibitor PKC412.
Chi HT; Ly BT; Kano Y; Tojo A; Watanabe T; Sato Y
Biochem Biophys Res Commun; 2012 Dec; 429(1-2):87-92. PubMed ID: 23131561
[TBL] [Abstract][Full Text] [Related]
38. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.
Azab AK; Azab F; Quang P; Maiso P; Sacco A; Ngo HT; Liu Y; Zhang Y; Morgan BL; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Jul; 17(13):4389-99. PubMed ID: 21521775
[TBL] [Abstract][Full Text] [Related]
39. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
[TBL] [Abstract][Full Text] [Related]
40. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.
Masih-Khan E; Trudel S; Heise C; Li Z; Paterson J; Nadeem V; Wei E; Roodman D; Claudio JO; Bergsagel PL; Stewart AK
Blood; 2006 Nov; 108(10):3465-71. PubMed ID: 16849642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
